Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company, has focused their efforts acquiring, developing and commercializing proprietary products that meet the needs of patients treated by gastroenterologists or primary care physicians. The company is currently commercializing ZEGERID® Capsules and Powder for Oral Suspension to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD). For further information, visit the Company’s web site at www.santarus.com.
- 17 years ago
QualityStocks
Santarus, Inc. (NASDAQ: SNTS)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Beeline Holdings, Inc. (NASDAQ: BLNE) Sees Potential Mortgage Activity Upside From $200 Billion MBS Purchase Plan
Beeline Holdings (NASDAQ: BLNE), a digital mortgage lender offering conventional and alternative mortgage solutions alongside blockchain-enabled…
-
QualityStocksNewsBreaks – Golden Triangle Ventures Inc. (OTC: GTVH) Signals Balance Sheet Reset and Operational Momentum in Corporate Update
Golden Triangle Ventures (OTC: GTVH) (“GTV”) today issued a corporate update outlining a transition into its next…
-
QualityStocksNewsBreaks – Diagnos Inc. (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A) Provides Regulatory Update on CARA AI Platform
This article has been disseminated on behalf of Diagnos Inc. and may include paid advertising.…